VTYX - Ventyx Biosciences Inc

VTYX - Ventyx Biosciences Inc

https://ventyxbio.com

Recent News

Powered by Alpha Vantage

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

GlobeNewswire • 2 weeks, 5 days ago • score: 0.12

SAN DIEGO, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Ventyx Biosciences, Inc. ( Nasdaq: VTYX ) ( "Ventyx", "Company" ) , a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today ...

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - Ventyx Biosciences ( NASDAQ:VTYX )

Benzinga • 2 weeks, 5 days ago • score: 0.03

SAN DIEGO, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Ventyx Biosciences, Inc. VTYX ( "Ventyx", "Company" ) , a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that ...

Ventyx ( VTYX ) Q2 Net Loss Drops 16%

Motley Fool • 1 month, 1 week ago • score: 0.19

Ventyx Biosciences ( NASDAQ:VTYX ) , a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and neurodegenerative diseases, released its second-quarter 2025 results on August 7, 2025. EPS ( GAAP ) was $0.38, which exceeded the analyst consensus estimate of $ ...

Ventyx Biosciences ( VTYX ) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks Commentary • 2 months ago • score: 0.36

Ventyx Biosciences (VTYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company is headquartered in Encinitas, California.

52W High

$3.39

52W Low

$0.78

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.95

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-22.93

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.86

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

4.11%

Institutions (25–75% balanced)

68.24%

Shares Outstanding

71,308,000

Float

53,556,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.66

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.49%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—